🔍 Advertising Regulation in Japan (Promotional Material Review) and Artificial Intelligence JP/EN
Ethics · Regulation · Technology — Pharma Practice Notes

The Anatomy of Failure ── Learning from real monitoring-report cases

We organize 227 inappropriate-promotion cases published in the MHLW monitoring-project reports (FY2016–2024) into 8 categories following the authority’s own taxonomy, each with the MHLW view, the competency that broke, and the next move.

Introduction — Get the Map First

Grab the whole picture before the episodes.
The map →
01

Promotion of Unapproved or Off-Label Indications and Dosage

33 cases. The 33 cases spanning 2016 to 2024 share one common thread: informatio
View cases →
02

Claims Lacking Evidence or Scientific Basis

69 cases. Category 02 covers 69 cases documented between 2016 and 2024. The unde
View cases →
03

Cherry-Picking, Data Manipulation, and Selective Presentation

33 cases. All 33 cases in this volume share one surface feature: data is present
View cases →
04

Exaggerated and Misleading Expressions

28 cases. "Ultimate," "the only one," "superior" — 28 cases where words not supp
View cases →
05

Emphasizing Efficacy While Downplaying Safety

22 cases. Across 22 cases recorded from 2016 to 2024, promotional representative
View cases →
06

Disparagement and Defamation of Competitors' Products

28 cases. This category covers 28 cases spanning 2018 to 2024. The structural pa
View cases →
07

Undisclosed Conflicts of Interest and Improper Conduct in Lectures and Prescribing Guidance

10 cases. This category contains 10 cases. The majority involve failure to discl
View cases →
08

Cross-Category Violations Rooted in Process Failures

4 cases. This category collects four cases that either fall outside categories
View cases →